ARS Pharmaceuticals, Inc.
SPRY
$13.77
-$0.87-5.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 49.93M | -19.13M | -12.52M | -10.29M | -7.17M |
| Total Depreciation and Amortization | 29.00K | 21.00K | 18.00K | 11.00K | 12.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.72M | 1.77M | 1.46M | 1.34M | 551.00K |
| Change in Net Operating Assets | -10.68M | 2.88M | 3.76M | 2.24M | -10.80M |
| Cash from Operations | 42.00M | -14.47M | -7.28M | -6.71M | -17.41M |
| Capital Expenditure | -302.00K | -140.00K | -38.00K | -83.00K | 91.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.46M | 16.96M | -12.61M | -8.43M | 25.95M |
| Cash from Investing | -101.76M | 16.82M | -12.65M | -8.51M | 26.04M |
| Total Debt Issued | 69.38M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.53M | 680.00K | 545.00K | 258.00K | 1.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 70.92M | 680.00K | 545.00K | 258.00K | 1.81M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.16M | 3.03M | -19.38M | -14.97M | 10.44M |